Canbridge Pharmaceuticals Inc banner
C

Canbridge Pharmaceuticals Inc
HKEX:1228

Watchlist Manager
Canbridge Pharmaceuticals Inc
HKEX:1228
Watchlist
Price: 2.59 HKD -0.77% Market Closed
Market Cap: HK$1.3B

Wall Street
Price Targets

Price Targets Summary
Canbridge Pharmaceuticals Inc

There are no price targets for Canbridge Pharmaceuticals Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Canbridge Pharmaceuticals Inc Competitors:
Price Targets
KRNY
Kearny Financial Corp
18% Upside
ACIU
AC Immune SA
240% Upside
PTCT
PTC Therapeutics Inc
34% Upside

Revenue
Forecast

4% / Year
Past Growth
90% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
4% / Year
Past Growth
90% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

For the last 13 years the compound annual growth rate for Canbridge Pharmaceuticals Inc's revenue is 4%. The projected CAGR for the next 2 years is 90%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
35%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
35%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Canbridge Pharmaceuticals Inc's stock price target?
Not Available

Canbridge Pharmaceuticals Inc doesn't have any price targets made by Wall Street professionals.

What is Canbridge Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
90%

For the last 13 years the compound annual growth rate for Canbridge Pharmaceuticals Inc's revenue is 4%. The projected CAGR for the next 2 years is 90%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett